Champions Biotechnlg (CSBR) 0.9500 $CSBR
Integrating Next-Generation Sequencing and Champions Oncology's TumorGrafts Provides Highly Accurate Prediction of Cancer Treatment Benefit, According to Results Published in Clinical Cancer Research
PR Newswire - Mon Apr 28, 7:00AM CDT
Results from a study published in Clinical Cancer Research demonstrate that oncologists were able to accurately predict which therapies patients would respond to by using a combination of next-generation sequencing and drug sensitivity testing in mouse avatars (Champions TumorGrafts®) developed by Champions Oncology (OTC: CSBR). The paper, titled "Integrated Next Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment," was published in the March issue of Clinical Cancer Research.
Publication of Article in Cancer Supports Use of Personalized Mouse Avatars to Predict Treatment Benefit in Patients
PR Newswire - Tue Apr 08, 11:16AM CDT
Data published in Cancer show the use of personalized patient-derived xenografts, or mouse avatars, accurately predicted treatment efficacy in all evaluated patients with advanced sarcoma. The results support the predictive capabilities of Champions TumorGrafts®, developed by Champions Oncology (OTC: CSBR), in providing actionable direction to oncologists to optimize cancer treatment. The article, titled "Patient-derived xenografts for individualized care in advanced sarcoma," was published online on April 4, 2014.
Champions Oncology to Present Posters on TumorGraft Application in Clinical and Research Settings at AACR Annual Meeting 2014
PR Newswire - Fri Apr 04, 3:00PM CDT
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the presentation of data from applications of Champions TumorGrafts® in clinical and research settings in multiple presentations at the American Association for Cancer Research (AACR) Annual Meeting 2014.
Champions Oncology Reports Results for the Third Quarter Ended January 31, 2014
PR Newswire - Thu Mar 13, 3:28PM CDT
Champions Oncology, Inc. (OTC: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the fiscal third quarter ended January 31, 2014.
Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 13
PR Newswire - Mon Mar 10, 9:45AM CDT
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the third quarter ended January 31, 2014 on Thursday, March 13, 2014, after market close.
Champions Oncology Expands Oncology Data Processing Capabilities with Appointment of Ido Ben-Zvi, Ph.D., as Director of Bioinformatics and Machine Learning
PR Newswire - Tue Mar 04, 7:00AM CST
HACKENSACK, N.J., March 4, 2014 /PRNewswire/-- Champions Oncology, Inc. (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the appointment of Ido Ben-Zvi, Ph.D., as Director of Bioinformatics and Machine Learning to exploit the company's wealth of oncology data from its TumorBank to support its Translational Oncology Solutions offerings for pharmaceutical companies.
Leading Regional Hospital Network in Asia to Offer Champions TumorGraft(TM) to Cancer Patients
PR Newswire - Wed Feb 26, 7:21AM CST
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that a leading hospital network in Asia, Parkway Cancer Centre (PCC), will begin offering Champions TumorGrafts(TM) to cancer patients at its three facilities in Singapore and network locations throughout South East Asia.
Champions Oncology Names Angela Davies, M.D., Chief Medical Officer
PR Newswire - Mon Jan 06, 3:05PM CST
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the appointment of Angela Davies, M.D., as Chief Medical Officer.
Champions Oncology Receives Accreditation From The Joint Commission
GlobeNewswire - Thu Jan 02, 3:00PM CST
Champions Oncology (OTC:CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today that its Baltimore, MD-based laboratory has received accreditation from The Joint Commission.
Champions Oncology Reports Results for the Quarter Ended October 31, 2013
GlobeNewswire - Thu Dec 12, 3:00PM CST
Champions Oncology, Inc. (OTC:CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today its financial results for the fiscal quarter ended October 31, 2013.
Enrollment Commenced in Barnabas Health and Champions Oncology Breast Cancer Research Trial
GlobeNewswire - Tue Dec 10, 3:00PM CST
Champions Oncology (OTC:CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, in conjunction with Barnabas Health, successfully enrolled the first patient in a groundbreaking breast cancer research trial.
FDA Nod for New Formulation of Teva's Treanda - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 18, 9:30AM CDT
Treanda, which was earlier available as an injection, will now be available in a liquid formulation as well.
Teva in Oncology Deals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 17, 12:30PM CDT
Teva has been working on strengthening its oncology portfolio.
Champions Oncology Inc posts lower loss of USD0.77m for the three months ended 31 July 2013
M2 - Mon Sep 16, 5:56AM CDT
Oncology drug company Champions Oncology Inc (Other OTC:CSBR) stated on Friday its loss from operations of USD0.77m for the fiscal quarter ended 31 July 2013.
UPDATE -- Champions Oncology Reports Results for the Quarter Ended July 31, 2013
GlobeNewswire - Fri Sep 13, 8:24AM CDT
Champions Oncology, Inc. (OTC:CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today its financial results for the fiscal quarter ended July 31, 2013.
Champions Oncology Reports Results for the Quarter Ended July 31, 2013
GlobeNewswire - Fri Sep 13, 5:30AM CDT
Champions Oncology, Inc. (OTC:CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today its financial results for the fiscal quarter ended July 31, 2013.
Champions Oncology and Teva Sign a Discovery and Drug Development Partnership
GlobeNewswire - Thu Sep 12, 3:07PM CDT
Champions Oncology Inc. (OTC:CSBR) ("Champions"
, a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the signing of a new discovery and drug development partnership with Teva Pharmaceutical Industries LTD (NYSE:TEVA) which will utilize Champions TumorGraft(TM) technology platform to enhance and accelerate the clinical development of several of Teva's oncology compounds.
Champions Oncology Receives Regulatory Approval From New York State Department of Health
GlobeNewswire - Tue Sep 10, 10:45AM CDT
Champions Oncology (OTC:CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today that it has received a clinical laboratory permit from the New York State Department of Health to provide its innovative Champions TumorGraft test to patients in New York. This approval, coupled with the existing Clinical Laboratory Improvement Amendment ("CLIA" certification and other state approvals, enables Champions to offer its services without restrictions in 48 states. Champions TumorGraft test is the first and only in vivo sensitivity test approved and provides oncologists and patients with information that can predict the potential effect of a chemotherapeutic regimen on the patient's specific tumor.
Champions Oncology to Announce First Quarter Financial Results on Friday, September 13
GlobeNewswire - Mon Sep 09, 3:00PM CDT
Champions Oncology (OTC:CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today that it will announce its financial and operational results for the first quarter ended July 31, 2013 on Friday, September 13.
Champions Oncology to Present at the Rodman & Renshaw Annual Global Investment Conference
GlobeNewswire - Wed Sep 04, 6:00AM CDT
Champions Oncology (OTC:CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today that CEO, Joel Ackerman, will be presenting at Rodman & Renshaw's 15 Annual Global Investment Conference being held September 8-10 at the Millennium Broadway Hotel in New York, NY.
Integrating Next-Generation Sequencing and Champions Oncology's TumorGrafts Provides Highly Accurate Prediction of Cancer Treatment Benefit, According to Results Published in Clinical Cancer Research
PR Newswire - Mon Apr 28, 7:00AM CDT
Results from a study published in Clinical Cancer Research demonstrate that oncologists were able to accurately predict which therapies patients would respond to by using a combination of next-generation sequencing and drug sensitivity testing in mouse avatars (Champions TumorGrafts®) developed by Champions Oncology (OTC: CSBR). The paper, titled "Integrated Next Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment," was published in the March issue of Clinical Cancer Research.
Publication of Article in Cancer Supports Use of Personalized Mouse Avatars to Predict Treatment Benefit in Patients
PR Newswire - Tue Apr 08, 11:16AM CDT
Data published in Cancer show the use of personalized patient-derived xenografts, or mouse avatars, accurately predicted treatment efficacy in all evaluated patients with advanced sarcoma. The results support the predictive capabilities of Champions TumorGrafts®, developed by Champions Oncology (OTC: CSBR), in providing actionable direction to oncologists to optimize cancer treatment. The article, titled "Patient-derived xenografts for individualized care in advanced sarcoma," was published online on April 4, 2014.
Champions Oncology to Present Posters on TumorGraft Application in Clinical and Research Settings at AACR Annual Meeting 2014
PR Newswire - Fri Apr 04, 3:00PM CDT
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the presentation of data from applications of Champions TumorGrafts® in clinical and research settings in multiple presentations at the American Association for Cancer Research (AACR) Annual Meeting 2014.
Champions Oncology Reports Results for the Third Quarter Ended January 31, 2014
PR Newswire - Thu Mar 13, 3:28PM CDT
Champions Oncology, Inc. (OTC: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the fiscal third quarter ended January 31, 2014.
Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 13
PR Newswire - Mon Mar 10, 9:45AM CDT
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the third quarter ended January 31, 2014 on Thursday, March 13, 2014, after market close.
Champions Oncology Expands Oncology Data Processing Capabilities with Appointment of Ido Ben-Zvi, Ph.D., as Director of Bioinformatics and Machine Learning
PR Newswire - Tue Mar 04, 7:00AM CST
HACKENSACK, N.J., March 4, 2014 /PRNewswire/-- Champions Oncology, Inc. (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the appointment of Ido Ben-Zvi, Ph.D., as Director of Bioinformatics and Machine Learning to exploit the company's wealth of oncology data from its TumorBank to support its Translational Oncology Solutions offerings for pharmaceutical companies.
Leading Regional Hospital Network in Asia to Offer Champions TumorGraft(TM) to Cancer Patients
PR Newswire - Wed Feb 26, 7:21AM CST
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that a leading hospital network in Asia, Parkway Cancer Centre (PCC), will begin offering Champions TumorGrafts(TM) to cancer patients at its three facilities in Singapore and network locations throughout South East Asia.
Champions Oncology Names Angela Davies, M.D., Chief Medical Officer
PR Newswire - Mon Jan 06, 3:05PM CST
Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the appointment of Angela Davies, M.D., as Chief Medical Officer.
Champions Oncology Receives Accreditation From The Joint Commission
GlobeNewswire - Thu Jan 02, 3:00PM CST
Champions Oncology (OTC:CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today that its Baltimore, MD-based laboratory has received accreditation from The Joint Commission.
Champions Oncology Reports Results for the Quarter Ended October 31, 2013
GlobeNewswire - Thu Dec 12, 3:00PM CST
Champions Oncology, Inc. (OTC:CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today its financial results for the fiscal quarter ended October 31, 2013.
Enrollment Commenced in Barnabas Health and Champions Oncology Breast Cancer Research Trial
GlobeNewswire - Tue Dec 10, 3:00PM CST
Champions Oncology (OTC:CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, in conjunction with Barnabas Health, successfully enrolled the first patient in a groundbreaking breast cancer research trial.
FDA Nod for New Formulation of Teva's Treanda - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 18, 9:30AM CDT
Treanda, which was earlier available as an injection, will now be available in a liquid formulation as well.
Teva in Oncology Deals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 17, 12:30PM CDT
Teva has been working on strengthening its oncology portfolio.
Champions Oncology Inc posts lower loss of USD0.77m for the three months ended 31 July 2013
M2 - Mon Sep 16, 5:56AM CDT
Oncology drug company Champions Oncology Inc (Other OTC:CSBR) stated on Friday its loss from operations of USD0.77m for the fiscal quarter ended 31 July 2013.
UPDATE -- Champions Oncology Reports Results for the Quarter Ended July 31, 2013
GlobeNewswire - Fri Sep 13, 8:24AM CDT
Champions Oncology, Inc. (OTC:CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today its financial results for the fiscal quarter ended July 31, 2013.
Champions Oncology Reports Results for the Quarter Ended July 31, 2013
GlobeNewswire - Fri Sep 13, 5:30AM CDT
Champions Oncology, Inc. (OTC:CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today its financial results for the fiscal quarter ended July 31, 2013.
Champions Oncology and Teva Sign a Discovery and Drug Development Partnership
GlobeNewswire - Thu Sep 12, 3:07PM CDT
Champions Oncology Inc. (OTC:CSBR) ("Champions"
, a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the signing of a new discovery and drug development partnership with Teva Pharmaceutical Industries LTD (NYSE:TEVA) which will utilize Champions TumorGraft(TM) technology platform to enhance and accelerate the clinical development of several of Teva's oncology compounds. Champions Oncology Receives Regulatory Approval From New York State Department of Health
GlobeNewswire - Tue Sep 10, 10:45AM CDT
Champions Oncology (OTC:CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today that it has received a clinical laboratory permit from the New York State Department of Health to provide its innovative Champions TumorGraft test to patients in New York. This approval, coupled with the existing Clinical Laboratory Improvement Amendment ("CLIA"
certification and other state approvals, enables Champions to offer its services without restrictions in 48 states. Champions TumorGraft test is the first and only in vivo sensitivity test approved and provides oncologists and patients with information that can predict the potential effect of a chemotherapeutic regimen on the patient's specific tumor. Champions Oncology to Announce First Quarter Financial Results on Friday, September 13
GlobeNewswire - Mon Sep 09, 3:00PM CDT
Champions Oncology (OTC:CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today that it will announce its financial and operational results for the first quarter ended July 31, 2013 on Friday, September 13.
Champions Oncology to Present at the Rodman & Renshaw Annual Global Investment Conference
GlobeNewswire - Wed Sep 04, 6:00AM CDT
Champions Oncology (OTC:CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today that CEO, Joel Ackerman, will be presenting at Rodman & Renshaw's 15 Annual Global Investment Conference being held September 8-10 at the Millennium Broadway Hotel in New York, NY.
